$PMCB
PharmaCyte Biotech Inc Stock $pmcb

$pmcb Overview Financials Valuation SEC Filings Company Website

2013 Q3 Form 10-Q Financial Statement

#000115707513000015 Filed on September 16, 2013

Income Statement

Concept	2013 Q3	2013 Q2	2013
Revenue	$0.00	$0.00	$12.16K
YoY Change	-100.0%	-100.0%	-81.73%
Cost Of Revenue		$0.00	$9.620K
YoY Change			-50.37%
Gross Profit	$0.00	$0.00	$2.540K
YoY Change	-100.0%	-100.0%	-94.62%
Gross Profit Margin			20.89%
Selling, General & Admin	$134.2K	$460.0K	$723.7K
YoY Change	-56.98%	-6.12%	69.35%
% of Gross Profit			28491.5%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$0.00	$0.00
YoY Change			-100.0%
% of Gross Profit			0.0%
Operating Expenses	$1.401M	$460.0K	$1.687M
YoY Change	156.81%	-6.12%	-15.5%
Operating Profit	-$1.401M	-$460.0K	-$1.684M
YoY Change	159.97%	-4.17%	-13.59%
Interest Expense	$10.35K	-$40.00K	$112.7K
YoY Change	-77.53%	-71.43%	-51.03%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00	$86.26K
YoY Change	-100.0%		72.97%
Pretax Income	-$4.670M	-$330.0K	-$1.600M
YoY Change	815.69%	-34.0%	-15.79%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$4.666M	-$330.0K	-$1.598M
YoY Change	814.05%	-34.0%	-15.86%
Net Earnings / Revenue			-13142.29%
Basic Earnings Per Share	-$0.01		$0.00
Diluted Earnings Per Share	-$8.949K	-$710.00	-$3.629K
COMMON SHARES
Basic Shares Outstanding	521.9M shares		441.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q3	2013 Q2	2013
SHORT-TERM ASSETS
Cash & Short-Term Investments	$210.0K	$200.0K	$200.0K
YoY Change	950.0%	900.0%	900.0%
Cash & Equivalents	$206.0K	$199.3K
Short-Term Investments
Other Short-Term Assets	$1.600M	$1.650M	$1.650M
YoY Change	36.75%	60.19%	60.19%
Inventory		$0.00	$0.00
Prepaid Expenses
Receivables			$0.00
Other Receivables			$0.00
Total Short-Term Assets	$1.804M	$1.848M	$1.850M
YoY Change	49.12%	74.56%	74.53%
LONG-TERM ASSETS
Property, Plant & Equipment			$0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$0.00	$0.00
YoY Change
Other Assets	$1.590M	$0.00	$1.030M
YoY Change	54.35%	-100.0%	0.0%
Total Long-Term Assets	$1.590M	$1.029M	$1.030M
YoY Change	55.87%	0.0%	0.0%
TOTAL ASSETS
Total Short-Term Assets	$1.804M	$1.848M	$1.850M
Total Long-Term Assets	$1.590M	$1.029M	$1.030M
Total Assets	$3.394M	$2.877M	$2.880M
YoY Change	52.21%	37.82%	37.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$295.6K	$352.0K	$770.0K
YoY Change	-63.51%	-51.79%	-29.36%
Accrued Expenses	$23.65K	$12.30K	$60.00K
YoY Change	-60.59%	-96.98%	-85.71%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$420.0K	$420.0K	$420.0K
YoY Change	-42.47%	-79.9%	-79.9%
Total Short-Term Liabilities	$994.2K	$3.798M	$3.800M
YoY Change	-75.33%	0.29%	0.26%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$994.2K	$3.798M	$3.800M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$994.2K	$3.798M	$3.800M
YoY Change	-75.33%	0.29%	0.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$46.11M	-$41.45M
YoY Change		4.01%
Common Stock	$53.70K	$48.21K
YoY Change		15.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.900M	-$1.501M	-$920.0K
YoY Change
Total Liabilities & Shareholders Equity	$3.394M	$2.877M	$2.880M
YoY Change	52.21%	37.82%	37.8%

Cashflow Statement

Concept	2013 Q3	2013 Q2	2013
OPERATING ACTIVITIES
Net Income	-$4.666M	-$330.0K	-$1.598M
YoY Change	814.05%	-34.0%	-15.86%
Depreciation, Depletion And Amortization		$0.00	$0.00
YoY Change			-100.0%
Cash From Operating Activities	-$159.7K	-$140.0K	-$390.4K
YoY Change	87.0%	180.0%	50.58%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$1.570M	-$170.0K	-$650.0K
YoY Change	685.0%	-10.53%	-25.29%
Cash From Investing Activities	-$1.569M	-$170.0K	-$646.8K
YoY Change	701.46%	-10.53%	-25.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$1.660M		$1.146M
YoY Change			5357.14%
Debt Paid & Issued, Net			$0.00
YoY Change			-100.0%
Cash From Financing Activities	$1.735M	470.0K	$1.221M
YoY Change	498.87%	113.64%	12.04%
NET CHANGE
Cash From Operating Activities	-$159.7K	-140.0K	-$390.4K
Cash From Investing Activities	-$1.569M	-170.0K	-$646.8K
Cash From Financing Activities	$1.735M	470.0K	$1.221M
Net Change In Cash	$6.735K	160.0K	$183.6K
YoY Change	-21.86%	-900.0%	-542.6%
FREE CASH FLOW
Cash From Operating Activities	-$159.7K	-$140.0K	-$390.4K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q3	us-gaap	Assets Assets	3394191	USD
CY2013Q2	us-gaap	Assets Assets	2876931	USD
CY2013Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	52259	USD
CY2013Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	29966	USD
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	351996	USD
CY2013Q3	us-gaap	Assets Held For Sale Other Noncurrent AssetsHeldForSaleOtherNoncurrent	0	USD
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	295569	USD
CY2013Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12300	USD
CY2013Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23646	USD
CY2013Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	47858815	USD
CY2013Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	39896440	USD
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1202127	USD
CY2012Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	181181	USD
CY2012Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-5695	USD
CY2013Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2013Q3	us-gaap	Business Acquisition Purchase Price Allocation Current Assets Prepaid Expense And Other Assets BusinessAcquisitionPurchasePriceAllocationCurrentAssetsPrepaidExpenseAndOtherAssets	1500000	USD
CY2013Q2	us-gaap	Business Acquisition Purchase Price Allocation Current Assets Prepaid Expense And Other Assets BusinessAcquisitionPurchasePriceAllocationCurrentAssetsPrepaidExpenseAndOtherAssets	1520980	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	1804361	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	1848153	USD
CY2013Q2	us-gaap	Assets Held For Sale Other Noncurrent AssetsHeldForSaleOtherNoncurrent	1028778	USD
CY2013Q3	us-gaap	Cash Cash	206038	USD
CY2013Q2	us-gaap	Cash Cash	199303	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15723	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24342	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	206038	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	199303	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	8619	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6735	USD
CY2013Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	59433600	shares
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1490000000	shares
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1490000000	shares
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	482106348	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	536941348	shares
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	536941348	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	482106348	shares
CY2013Q3	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	100000	USD
CY2013Q2	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	0	USD
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	48211	USD
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	53695	USD
CY2013Q3	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:14px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has no significant off-balance-sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. The Company maintains the majority of its cash balances with one financial institution in the form of demand deposits.</font></div></div>
CY2012Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2581	USD
CY2013Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
CY2012Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	66967	USD
CY2013Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	11346	USD
CY2013Q3	us-gaap	Contractual Obligation ContractualObligation	400000	USD
CY2013Q3	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	720000	USD
CY2013Q3	us-gaap	Cost Of Revenue CostOfRevenue		USD
CY2012Q3	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
CY2013Q2	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	4475000	USD
CY2013Q2	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	471010	USD
CY2013Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.08
CY2013Q2	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	227569	USD
CY2013Q3	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	224974	USD
CY2013Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2013Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	393157	USD
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2012Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2012Q3	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2012Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	18549	USD
CY2013Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	965	USD
CY2012Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2774	USD
CY2013Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2013Q3	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-29547	USD
CY2012Q3	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-88821	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	10351	USD
CY2013Q3	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	32392	USD
CY2011	us-gaap	Gain Loss On Sale Of Debt Investments GainLossOnSaleOfDebtInvestments	95000	USD
CY2013Q3	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	1312328	USD
CY2012Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2013Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3973795	USD
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	230006	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	119206	USD
CY2012Q3	us-gaap	Gross Profit GrossProfit	6626	USD
CY2013Q3	us-gaap	Gross Profit GrossProfit	0	USD
CY2013Q3	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2012Q3	us-gaap	Interest Expense InterestExpense	46063	USD
CY2012Q3	us-gaap	Interest Paid InterestPaid	0	USD
CY2013Q3	us-gaap	Interest Paid InterestPaid	0	USD
CY2013Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	31095	USD
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3265676	USD
CY2012Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	28269	USD
CY2013Q2	us-gaap	Liabilities Liabilities	3798387	USD
CY2013Q3	us-gaap	Liabilities Liabilities	994155	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2876931	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3394191	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3798387	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	994155	USD
CY2013Q3	us-gaap	Loans Payable Current LoansPayableCurrent	420000	USD
CY2013Q2	us-gaap	Loans Payable Current LoansPayableCurrent	420000	USD
CY2012Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	289757	USD
CY2013Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1735259	USD
CY2013Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1568850	USD
CY2012Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-195750	USD
CY2012Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-85388	USD
CY2013Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-159674	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-4666367	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-510517	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-1598102	USD
CY2013Q3	us-gaap	Notes Payable NotesPayable	20000	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	1400691	USD
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	545412	USD
CY2012Q3	nvlx	Gains Losses On Forgiveness Of Debt GainsLossesOnForgivenessOfDebt	71742	USD
CY2013Q3	nvlx	Increase In Accrued Interest Related Party IncreaseInAccruedInterestRelatedParty	7902	USD
CY2013Q3	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	702061	USD
CY2013Q3	us-gaap	Payments For Proceeds From Previous Acquisition PaymentsForProceedsFromPreviousAcquisition	1568850	USD
CY2012Q3	us-gaap	Payments For Proceeds From Previous Acquisition PaymentsForProceedsFromPreviousAcquisition	195750	USD
CY2013Q3	us-gaap	Preferred Stock Conversions Inducements PreferredStockConversionsInducements	640000	USD
CY2012Q3	nvlx	Increase In Accrued Interest Related Party IncreaseInAccruedInterestRelatedParty	9241	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1400691	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-538786	USD
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1589830	USD
CY2013Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2012Q3	us-gaap	Other Expenses OtherExpenses	-2590	USD
CY2013Q3	us-gaap	Other Expenses OtherExpenses	0	USD
CY2013Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0	USD
CY2013Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2341106	USD
CY2012Q3	us-gaap	Preferred Stock Conversions Inducements PreferredStockConversionsInducements	0	USD
CY2011Q1	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	22.86
CY2011Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	3500	shares
CY2013Q2	us-gaap	Preferred Stock Value PreferredStockValue	580000	USD
CY2013Q3	us-gaap	Preferred Stock Value PreferredStockValue	500000	USD
CY2011Q1	us-gaap	Preferred Stock Value PreferredStockValue	80000	USD
CY2013Q3	us-gaap	Preferred Stock Voting Rights PreferredStockVotingRights	50000
CY2013Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	127870	USD
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	98323	USD
CY2013Q3	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-top:14px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain items in the prior year financial statements have been reclassified for comparative purposes to conform to the presentation in the current period’s presentation. These reclassifications have no effect on the previously reported income (loss).</font></div></div>
CY2012Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2013Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1660000	USD
CY2012Q3	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	250000	USD
CY2013Q3	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2012Q3	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	39757	USD
CY2013Q3	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	77853	USD
CY2012Q3	us-gaap	Professional Fees ProfessionalFees	52243	USD
CY2013Q3	us-gaap	Professional Fees ProfessionalFees	64358	USD
CY2011Q1	nvlx	Original Valuation Of Preferred Stock Per Share Based On Prior Issuance OriginalValuationOfPreferredStockPerShareBasedOnPriorIssuance	50.00
CY2013Q3	nvlx	Shares Issued For Settlement Of Debt Amount SharesIssuedForSettlementOfDebtAmount	4486251	USD
CY2013	nvlx	Shares Issued For Settlement Of Debt Amount SharesIssuedForSettlementOfDebtAmount	143596	USD
CY2013	nvlx	Stock Issued During Period For Private Placement Memo Amount StockIssuedDuringPeriodForPrivatePlacementMemoAmount	1238204	USD
CY2012Q3	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
CY2013Q3	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	2594	USD
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-46112474	USD
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41446107	USD
CY2013Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1660000	USD
CY2013	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	653696	USD
CY2013Q3	us-gaap	Revenues Revenues	0	USD
CY2012Q3	us-gaap	Revenues Revenues	6626	USD
CY2012Q3	us-gaap	Sales Revenue Net SalesRevenueNet	6626	USD
CY2013Q3	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
CY2012Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	81982	USD
CY2013Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	15000	USD
CY2012Q3	us-gaap	Share Based Compensation ShareBasedCompensation	319181	USD
CY2013Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1201608	USD
CY2013	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	331000	USD
CY2013Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	9600	USD
CY2013Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1192008	USD
CY2013Q3	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1192008	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	-1501456	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	1900036	USD
CY2012Q2	us-gaap	Stockholders Equity StockholdersEquity	-2279850	USD
CY2013Q3	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:14px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>
CY2012Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	419566403	shares
CY2013Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	521873196	shares
CY2012Q3	nvlx	Common Stock Issued For Debt CommonStockIssuedForDebt	98596	USD
CY2013Q3	nvlx	Common Stock Issued For Debt CommonStockIssuedForDebt	533598	USD
CY2013Q3	nvlx	Gain On Repayment Of Debt GainOnRepaymentOfDebt	21142	USD
CY2013Q3	nvlx	Gains Losses On Forgiveness Of Debt GainsLossesOnForgivenessOfDebt	1358470	USD
CY2013Q3	nvlx	Stock Issued During Period For Private Placement Memo Amount StockIssuedDuringPeriodForPrivatePlacementMemoAmount	1560000	USD
CY2013Q2	nvlx	Stock Pledged As Security For Payment Of Indebtedness StockPledgedAsSecurityForPaymentOfIndebtedness	8230637	shares
CY2013Q3	nvlx	Working Capital WorkingCapital	810206	USD
CY2013Q3	dei	Amendment Flag AmendmentFlag	false
CY2013Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-30
CY2013Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2013Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2013Q3	dei	Document Period End Date DocumentPeriodEndDate	2013-07-31
CY2013Q3	dei	Document Type DocumentType	10-Q
CY2013Q3	dei	Entity Central Index Key EntityCentralIndexKey	0001157075
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	637241348	shares
CY2013Q3	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2013Q3	dei	Entity Registrant Name EntityRegistrantName	NUVILEX, INC.

Files In Submission

Name	View Source	Status
0001157075-13-000015-index-headers.html	Edgar Link	pending
0001157075-13-000015-index.html	Edgar Link	pending
0001157075-13-000015.txt	Edgar Link	pending
0001157075-13-000015-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
nvlx-07312013x10q.htm	Edgar Link	pending
nvlx-07312013xex311.htm	Edgar Link	pending
nvlx-07312013xex312.htm	Edgar Link	pending
nvlx-07312013xex321.htm	Edgar Link	pending
nvlx-07312013xex322.htm	Edgar Link	pending
nvlx-20130731.xml	Edgar Link	completed
nvlx-20130731.xsd	Edgar Link	pending
nvlx-20130731_cal.xml	Edgar Link	unprocessable
nvlx-20130731_def.xml	Edgar Link	unprocessable
nvlx-20130731_lab.xml	Edgar Link	unprocessable
nvlx-20130731_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PMCB
PharmaCyte Biotech Inc Stock $pmcb

2013 Q3 Form 10-Q Financial Statement

#000115707513000015 Filed on September 16, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PMCB PharmaCyte Biotech Inc Stock $pmcb

2013 Q3 Form 10-Q Financial Statement

#000115707513000015 Filed on September 16, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PMCB
PharmaCyte Biotech Inc Stock $pmcb